|GeoVax Labs, Inc.|
1900 Lake Park Drive
United States - Map
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines against infectious diseases using its novel vaccine platform. The company focuses on developing vaccines against human immunodeficiency virus (HIV); Zika virus; and hemorrhagic fever viruses, such as Ebola, Marburg, and Lassa Fever, as well as vaccines for use in cancer immunotherapy. Its vaccines under development include GOVX-B11, which has completed Phase 2a clinical trials to treat clade B subtype of HIV virus; and vaccines in preclinical research include vaccine candidate for the clade C subtype of HIV virus. The company has a collaborative research agreement with the University of Pittsburgh for selection and testing of vaccine candidates; and the University of Georgia to develop and test a vaccine to prevent the Zika virus infection. GeoVax Labs, Inc. was founded in 2001 and is based in Smyrna, Georgia.
|Dr. Robert T. McNally Ph.D.,
Chief Exec. Officer, Pres and Director
|Dr. Harriet Latham Robinson Ph.D.,
Co-Founder, Chief Scientific Officer and Director
|Mr. Mark W. Reynolds CPA,
Chief Financial Officer and Corp. Sec.
|Mr. Donald G. Hildebrand ,
Founder, Chairman Emeritus and Consultant
|Dr. Farshad Guirakhoo Ph.D.,
Sr. VP of R&D
|Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|